pSivida acquired the specialty biopharmaceutical company Icon Bioscience rebranded as EyePoint Pharmaceuticals. Financial terms were not disclosed. The Company has entered into a financial agreement with EW Healthcare Partners. EW Healthcare Partners and a third party investor will make equity investments in pSivida for a total of up to approximately $60m. In addition, SWK Holdings has agreed to provide pSivida with up to $20m in a debt facility. The Company will use these resources to finance the Icon acquisition and prepare for the commercial development of Dexycu, as well as pSivida’s Durasert treatment for posterior segment uveitis, which uses nanotechnology to inject a microinsert for the treatment of noninfectious uveitis for up to 3 years. In addition​, due to a significant decrease in the proportion of the Company's common stock held by Australian shareholders, low trading activity and the costs of maintaining the listing pSivida has requested that its shares be delisted from trading on the Australian Securities Exchange. “Today’s announcements significantly accelerate the transformation of pSivida into a specialty biopharmaceutical company with the potential to launch two ophthalmic products in the first half of 2019 with the FDA approval of DEXYCU, and active regulatory review of Durasert micro-insert for posterior segment non-infectious uveitis. Our goal is to leverage the commercial infrastructure we are building and become a sustainable growth company,” said Nancy Lurker President and CEO of pSivida.